Summary
0.71 0.03(3.83%)10/04/2024
OptiNose Inc (OPTN)
OptiNose Inc (OPTN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 3.96 | 3.00 | -28.65 | -31.95 | -47.71 | -43.56 | -96.54 | -96.37 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 0.71 | |
| Open | 0.69 | |
| High | 0.72 | |
| Low | 0.69 | |
| Volume | 292,934 | |
| Change | 0.03 | |
| Change % | 3.96 | |
| Avg Volume (20 Days) | 465,147 | |
| Volume/Avg Volume (20 Days) Ratio | 0.63 | |
| 52 Week Range | 0.65 - 2.10 | |
| Price vs 52 Week High | -66.14% | |
| Price vs 52 Week Low | 9.40% | |
| Range | 3.06 | |
| Gap Up/Down | -0.01 | |
Fundamentals | ||
| Market Capitalization (Mln) | 103 | |
| EBIDTA | -100,123,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 9.20 | |
| Book Value | 0.1280 | |
| Earnings Per Share | -1.7100 | |
| EPS Estimate Current Quarter | -0.3600 | |
| EPS Estimate Next Quarter | -0.2800 | |
| EPS Estimate Current Year | -1.5000 | |
| EPS Estimate Next Year | -0.6400 | |
| Diluted EPS (TTM) | -1.7100 | |
| Revenues | ||
| Profit Marging | -1.3219 | |
| Operating Marging (TTM) | -1.0985 | |
| Return on asset (TTM) | -0.3005 | |
| Return on equity (TTM) | -10.5050 | |
| Revenue TTM | 68,490,000 | |
| Revenue per share TTM | 1.2930 | |
| Quarterly Revenue Growth (YOY) | 0.4140 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 41,597,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 24.2559 | |
| Revenue Enterprise Value | 2.6049 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 82,199,600 | |
| Shares Float | 33,525,172 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 10.28 | |
| Institutions (%) | 47.81 | |
09/05 09:00 EST - globenewswire.com
New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery
YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the peer-review publication of a paper titled, “EDS-FLU efficacy in patients with chronic rhinosinusitis with or without prior sinus surgery in ReOpen1 and ReOpen2 randomized controlled trials”1 in the International Forum of Allergy & Rhinology, the journal of the American Rhinologic Society.
New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery
YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the peer-review publication of a paper titled, “EDS-FLU efficacy in patients with chronic rhinosinusitis with or without prior sinus surgery in ReOpen1 and ReOpen2 randomized controlled trials”1 in the International Forum of Allergy & Rhinology, the journal of the American Rhinologic Society.
08/26 09:00 EST - globenewswire.com
Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference
YARDLEY, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024 at 10:00 a.m. ET.
Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference
YARDLEY, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024 at 10:00 a.m. ET.
08/11 07:17 EST - seekingalpha.com
OptiNose, Inc. (OPTN) Q2 2024 Earnings Call Transcript
OptiNose, Inc. (NASDAQ:OPTN ) Q2 2024 Results Conference Call August 8, 2024 8:00 AM ET Company Participants Jonathan Neely - VP, IR & Business Development Dr. Ramy Mahmoud - CEO Paul Spence - Chief Commercial Officer Conference Call Participants Schuyler van den Broek - Piper Sandler Thomas Flaten - Lake Street Capital Markets Operator Hello, and welcome to the OptiNose Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
OptiNose, Inc. (OPTN) Q2 2024 Earnings Call Transcript
OptiNose, Inc. (NASDAQ:OPTN ) Q2 2024 Results Conference Call August 8, 2024 8:00 AM ET Company Participants Jonathan Neely - VP, IR & Business Development Dr. Ramy Mahmoud - CEO Paul Spence - Chief Commercial Officer Conference Call Participants Schuyler van den Broek - Piper Sandler Thomas Flaten - Lake Street Capital Markets Operator Hello, and welcome to the OptiNose Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
08/08 09:26 EST - zacks.com
OptiNose (OPTN) Reports Q2 Loss, Lags Revenue Estimates
OptiNose (OPTN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.02 per share a year ago.
OptiNose (OPTN) Reports Q2 Loss, Lags Revenue Estimates
OptiNose (OPTN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.02 per share a year ago.
08/02 08:30 EST - globenewswire.com
Optinose Announces Reporting Date for Second Quarter 2024 Financial Results
Conference Call and Webcast to be held August 8, 2024, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held August 8, 2024, at 8:00 a.m. Eastern Time
Optinose Announces Reporting Date for Second Quarter 2024 Financial Results
Conference Call and Webcast to be held August 8, 2024, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held August 8, 2024, at 8:00 a.m. Eastern Time
07/02 16:27 EST - investorplace.com
7 Little-Known Penny Stocks That Can Turn $10K Into $1 Million
The stock market rally has been showing no sign of stopping, and while most of it has been driven by Big Tech, it is worth looking into some little-known penny stocks. These stocks usually see huge breakouts and trade at big premiums during bullish rallies.
7 Little-Known Penny Stocks That Can Turn $10K Into $1 Million
The stock market rally has been showing no sign of stopping, and while most of it has been driven by Big Tech, it is worth looking into some little-known penny stocks. These stocks usually see huge breakouts and trade at big premiums during bullish rallies.
06/27 07:00 EST - globenewswire.com
Expanded Access to XHANCE with Addition to National Commercial Formularies
YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that XHANCE® (fluticasone propionate) has been added to Express Scripts' national formularies, including the National Preferred, Flex, and Basic formularies, among the largest commercial formularies in the U.S. with more than 24 million lives.
Expanded Access to XHANCE with Addition to National Commercial Formularies
YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that XHANCE® (fluticasone propionate) has been added to Express Scripts' national formularies, including the National Preferred, Flex, and Basic formularies, among the largest commercial formularies in the U.S. with more than 24 million lives.
05/17 20:55 EST - seekingalpha.com
OptiNose, Inc. (OPTN) Q1 2024 Earnings Call Transcript
OptiNose, Inc. (NASDAQ:OPTN ) Q1 2024 Results Conference Call May 15, 2024 10:00 AM ET Company Participants Jonathan Neely - VP, IR & Business Development Dr. Ramy Mahmoud - CEO Conference Call Participants Thomas Flaten - Lake Street Capital Markets Schuyler van den Broek - Piper Sandler Glen Santangelo - Jefferies Matthew Caufield - H.C. Wainwright Operator Good day, and thank you for standing by.
OptiNose, Inc. (OPTN) Q1 2024 Earnings Call Transcript
OptiNose, Inc. (NASDAQ:OPTN ) Q1 2024 Results Conference Call May 15, 2024 10:00 AM ET Company Participants Jonathan Neely - VP, IR & Business Development Dr. Ramy Mahmoud - CEO Conference Call Participants Thomas Flaten - Lake Street Capital Markets Schuyler van den Broek - Piper Sandler Glen Santangelo - Jefferies Matthew Caufield - H.C. Wainwright Operator Good day, and thank you for standing by.
05/17 12:00 EST - globenewswire.com
Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024 at 11:30 a.m. ET.
Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024 at 11:30 a.m. ET.
05/14 09:11 EST - zacks.com
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
OptiNose (OPTN) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.17 per share a year ago.
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
OptiNose (OPTN) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.17 per share a year ago.
05/14 07:00 EST - globenewswire.com
Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights
Company reports Q1 2024 XHANCE net revenue of $14.9 million, an increase of 26% compared to Q1 2023 Company expects full year 2024 XHANCE net revenues to be between $85.0 to $95.0 million Company expects peak year XHANCE net revenues of at least $300 million from current specialist focused prescriber audience Company expects to produce positive income from operations (GAAP) for full year 2025 Conference call and webcast to be held today at 10:00 a.m. Eastern Time YARDLEY, Pa.
Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights
Company reports Q1 2024 XHANCE net revenue of $14.9 million, an increase of 26% compared to Q1 2023 Company expects full year 2024 XHANCE net revenues to be between $85.0 to $95.0 million Company expects peak year XHANCE net revenues of at least $300 million from current specialist focused prescriber audience Company expects to produce positive income from operations (GAAP) for full year 2025 Conference call and webcast to be held today at 10:00 a.m. Eastern Time YARDLEY, Pa.
05/10 14:56 EST - globenewswire.com
Optinose Announces Reporting Date for First Quarter 2024 Financial Results
Conference Call and Webcast to be held May 14, 2024, at 10:00 a.m. Eastern Time Conference Call and Webcast to be held May 14, 2024, at 10:00 a.m. Eastern Time
Optinose Announces Reporting Date for First Quarter 2024 Financial Results
Conference Call and Webcast to be held May 14, 2024, at 10:00 a.m. Eastern Time Conference Call and Webcast to be held May 14, 2024, at 10:00 a.m. Eastern Time
05/02 11:06 EST - zacks.com
Will OptiNose (OPTN) Report Negative Q1 Earnings? What You Should Know
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will OptiNose (OPTN) Report Negative Q1 Earnings? What You Should Know
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/25 11:07 EST - investorplace.com
Why Are Stocks Down Today?
Stocks are down today and investors wondering why have come to the right place as we have all the details behind the market slump on Thursday! The first bit of news that is pulling stocks down today comes from Meta Platforms (NASDAQ: META ).
Why Are Stocks Down Today?
Stocks are down today and investors wondering why have come to the right place as we have all the details behind the market slump on Thursday! The first bit of news that is pulling stocks down today comes from Meta Platforms (NASDAQ: META ).
04/25 10:51 EST - investorplace.com
Why Is OptiNose (OPTN) Stock Up 12% Today?
OptiNose (NASDAQ: OPTN ) stock is taking off on Thursday after the company provided investors with an update on XHANCE following an expansion of its use by the Food and Drug Administration (FDA). The expansion news includes the FDA signing off on XHANCE being used as a treatment for adult patients with chronic rhinosinusitis without nasal polyps.
Why Is OptiNose (OPTN) Stock Up 12% Today?
OptiNose (NASDAQ: OPTN ) stock is taking off on Thursday after the company provided investors with an update on XHANCE following an expansion of its use by the Food and Drug Administration (FDA). The expansion news includes the FDA signing off on XHANCE being used as a treatment for adult patients with chronic rhinosinusitis without nasal polyps.
04/25 07:00 EST - globenewswire.com
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
Conference Call and Webcast to be held April 25, 2024, at 10:00 a.m. Eastern Time Conference Call and Webcast to be held April 25, 2024, at 10:00 a.m. Eastern Time
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
Conference Call and Webcast to be held April 25, 2024, at 10:00 a.m. Eastern Time Conference Call and Webcast to be held April 25, 2024, at 10:00 a.m. Eastern Time
04/04 16:01 EST - globenewswire.com
Optinose to Present at the Needham Virtual Healthcare Conference
YARDLEY, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 10, 2024 at 2:15 p.m. ET.
Optinose to Present at the Needham Virtual Healthcare Conference
YARDLEY, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 10, 2024 at 2:15 p.m. ET.
03/15 15:34 EST - globenewswire.com
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
ReOpen was th e first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
ReOpen was th e first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps
03/07 09:16 EST - zacks.com
OptiNose (OPTN) Reports Q4 Loss, Lags Revenue Estimates
OptiNose (OPTN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.17 per share a year ago.
OptiNose (OPTN) Reports Q4 Loss, Lags Revenue Estimates
OptiNose (OPTN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.17 per share a year ago.
03/07 07:00 EST - globenewswire.com
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
PDUFA target action date is March 16, 2024, for the Company's sNDA. If approved, the Company is prepared for launch of XHANCE for treatment of patients diagnosed with chronic sinusitis
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
PDUFA target action date is March 16, 2024, for the Company's sNDA. If approved, the Company is prepared for launch of XHANCE for treatment of patients diagnosed with chronic sinusitis